Six Dragonfly-developed drugs are in clinical trials now, with our lead drug in Phase 2. Four more Dragonfly-developed drugs are expected in the clinic by the end of 2023.
DRAGONFLY invents novel therapies that harness the body’s immune system, for vastly improved Patient Outcomes.
In collaboration with AbbVie, BMS, Gilead and Merck, our novel TriNKET™ and CYTOKINE platforms have generated 10 Drug Candidates that have been handed off to partners.
Activating the Immune
System to Fight Disease
Gilead joins a lineup of Big Pharma partners betting big on
TriNKETs, with a $300M cash ante to get started on a 5T4
Gilead’s team, now guided by R&D chief Flavius Martin, gets worldwide rights to DF7001, Dragonfly’s 5T4-targeting therapy designed to drag natural killer — NK cells — along with other cancer killing T cells into the tumor microenvironment.. [ENDPOINTS NEWS]
Tri-Specific NK cell Engager Therapy
Proprietary long-half-life cytokines
Two Proprietary Platforms
DRAGONFLY is a clinical-stage biotech that has developed a deep portfolio of drugs built on two unique platforms: first-in-class tri-specific NK engagers (“TriNKETs”)
and best-in-class CYTOKINEs – each with lead
drugs in the clinic with encouraging results.
Pipeline for Patients
In addition to a set of advanced programs in the clinic or handed off to our pharma partners, DRAGONFLY is developing 16+ TriNKETs and multiple CYTOKINES across a broad range of fields, including autoimmune and inflammatory diseases, fibrosis, neurology, infectious disease, and oncology.